A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
about
Monitoring of the Immune Dysfunction in Cancer PatientsStandard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Pharmacological activation of wild-type p53 in the therapy of leukemia.The importance of correctly timing cancer immunotherapy.Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.
P2860
Q28072712-BC10C280-116A-4FE2-A235-DA79731F3140Q37559245-45F42E2F-8E6C-4355-A3AB-AFAF19D91909Q38600417-85BEA279-19E4-4081-BDA8-4407F9A4FCAEQ38872029-B4220678-9233-405A-9EA4-143EA21CD27EQ38995979-3F30FEE2-16E8-4CA1-B38E-172821BD88CDQ40802250-6BA91613-61CE-4341-807A-46E2C4CF27DAQ47122613-547F9ACA-33C0-498D-81BC-0A45A4F778C3Q47561666-79EA6C8C-F5C4-4C20-8962-3240AE75AD87Q47581436-000BC8A7-8C16-4683-852B-BF270AC30258Q52758913-B5B8E08B-B416-4D4F-A7BF-7FC83909898F
P2860
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@ast
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@en
type
label
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@ast
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@en
prefLabel
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@ast
A phase 1/2 study combining ge ...... inum-resistant ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
A phase 1/2 study combining ge ...... tinum-resistant ovarian cancer
@en
P2093
An K L Reyners
Arien R van Erkel
Cornelis J M Melief
Eveline M Dijkgraaf
Hans W Nijman
Jacobus J M van der Hoeven
Marij J P Welters
Mariëtte I E van Poelgeest
Renske Goedemans
Saskia J A M Santegoets
P2860
P304
32228-32243
P356
10.18632/ONCOTARGET.4772
P407
P577
2015-10-01T00:00:00Z